Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
AssigneeOregon Health & Science University
InventorsLouis J. Picker, Michael A. Jarvis, Jay A. Nelson
Life of this patent
Estimating the term…
Loading patent…
AssigneeOregon Health & Science University
InventorsLouis J. Picker, Michael A. Jarvis, Jay A. Nelson
Estimating the term…
Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors.
A method for the treatment or prevention of HIV, the method comprising infecting a human subject in need thereof with at least one recombinant vaccine vector,
8-39. (canceled)
A method for the treatment or prevention of HIV, the method comprising administering a pharmaceutical composition to a human subject in need thereof,
A method for the treatment or prevention of HIV, the method comprising infecting an immunocompetent, HCMV-seropositive human subject in need thereof with at least one recombinant vaccine vector;
Dependencies are inferred from the claim text.